Encompass Health’s (EHC) “Strong-Buy” Rating Reaffirmed at Raymond James

Encompass Health (NYSE:EHC)‘s stock had its “strong-buy” rating reaffirmed by analysts at Raymond James in a research note issued to investors on Friday, Benzinga reports. They currently have a $95.00 price target on the stock, up from their previous price target of $85.00. Raymond James’ price target would indicate a potential upside of 14.87% from the company’s previous close.

A number of other analysts have also recently weighed in on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $83.00 target price on shares of Encompass Health in a research note on Friday, February 9th. Mizuho boosted their target price on shares of Encompass Health from $93.00 to $95.00 and gave the company a “buy” rating in a report on Thursday. William Blair restated an “outperform” rating on shares of Encompass Health in a report on Wednesday, February 7th. Barclays boosted their target price on shares of Encompass Health from $101.00 to $108.00 and gave the company an “overweight” rating in a report on Thursday. Finally, Truist Financial boosted their target price on shares of Encompass Health from $82.00 to $86.00 and gave the company a “buy” rating in a report on Friday, February 9th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Encompass Health presently has a consensus rating of “Buy” and a consensus price target of $86.56.

Encompass Health Price Performance

NYSE EHC traded down $0.03 during midday trading on Friday, hitting $82.70. The company had a trading volume of 335,959 shares, compared to its average volume of 668,036. The company has a current ratio of 1.28, a quick ratio of 1.28 and a debt-to-equity ratio of 1.19. Encompass Health has a twelve month low of $57.55 and a twelve month high of $85.84. The company has a market capitalization of $8.28 billion, a PE ratio of 22.35, a P/E/G ratio of 1.53 and a beta of 0.94. The firm has a 50-day moving average price of $78.07 and a 200-day moving average price of $70.76.

Encompass Health (NYSE:EHC) last announced its quarterly earnings results on Wednesday, April 24th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.93 by $0.19. The company had revenue of $1.32 billion for the quarter, compared to analyst estimates of $1.27 billion. Encompass Health had a net margin of 7.60% and a return on equity of 18.48%. The firm’s revenue was up 13.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.88 EPS. As a group, analysts anticipate that Encompass Health will post 3.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Encompass Health

Several hedge funds and other institutional investors have recently made changes to their positions in EHC. Principal Securities Inc. bought a new stake in shares of Encompass Health during the fourth quarter worth about $25,000. Benjamin F. Edwards & Company Inc. lifted its stake in shares of Encompass Health by 360.2% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 405 shares of the company’s stock valued at $27,000 after buying an additional 317 shares in the last quarter. McGlone Suttner Wealth Management Inc. purchased a new stake in shares of Encompass Health during the 4th quarter valued at approximately $30,000. GAMMA Investing LLC purchased a new stake in shares of Encompass Health during the 4th quarter valued at approximately $33,000. Finally, C M Bidwell & Associates Ltd. purchased a new stake in Encompass Health in the 3rd quarter worth approximately $35,000. 97.25% of the stock is owned by institutional investors.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.